Results 191 to 200 of about 2,296,637 (249)

Cannabis Legalization and Cannabis Use Disorder by Sex in Veterans Health Administration Patients, 2005-2019. [PDF]

Subst Use Misuse
Wisell CG, Hasin DS, Wall MM, Alschuler D, Malte C, McDowell Y, Olfson M, Keyes KM, Cerdá M, Maynard CC, Keyhani S, Martins SS, Mannes ZL, Livne O, Fink DS, Bujno JM, Stohl M, Saxon AJ, Simpson TL.   +18 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Traumatic Brain Injury among Native Hawaiian and Pacific Islander Veterans accessing Veterans Health Administration Homeless Services: A Preliminary Examination. [PDF]

Hawaii J Health Soc Welf
Holliday R, Lum S, Kindler C, Jordan SE, Aase D, Iwamasa GY, Liu S, Tsai J, Molella LE, Monteith LL.   +9 more
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

The 21st century marks a rise in TURP retreatment rates: an analysis of Veterans Health Administration data. [PDF]

World J Urol
Nackeeran S, Morgan KM, Chen H, Anger JT, Sur RL, Sheetz T.   +5 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Health Care Costs Associated With Norovirus at the Veterans Health Administration.

JAMA Netw Open
Cates JE, Nelson RE, Suo Y, Parashar UD, Lucero-Obusan CA, Holodniy M, Mirza SA.   +6 more
europepmc   +1 more source

"Treat us Like Human Beings": Messages and Recommendations to U.S. Policymakers and Veterans Health Administration Providers from a Qualitative Inquiry Into the Health Experiences of Gulf War Veterans With Gulf War Illness. [PDF]

J Patient Exp
Montague KA, Lafferty M, Graham M, Nugent SM.   +3 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

First-Line β-Blocker Use for Hypertension in the Veterans Health Administration. [PDF]

JAMA Netw Open
Derington CG, Berchie RO, Mohanty AF, Jacobs JA, Xu Y, King JB, Rethy L, Cushman WC, Zickmund SL, Ho PM, Raghavan S, Cohen JB, Bress AP.   +12 more
europepmc   +1 more source